{"protocolSection":{"identificationModule":{"nctId":"NCT03010462","orgStudyIdInfo":{"id":"NX103391"},"organization":{"fullName":"Nexstim Ltd","class":"INDUSTRY"},"briefTitle":"Electric Field Navigated 1hz Rtms for Post-stroke Motor Recovery Trial","officialTitle":"A Prospective, Multi-center, Randomized, Sham-controlled Trial to Determine the Therapeutic Effects of Navigation Guided 1 hz Rtms Administered to the Contralesional Hemisphere as Adjuvant to Task-oriented Rehabilitation in Patients With Ischemic Stroke","acronym":"E-FIT"},"statusModule":{"statusVerifiedDate":"2021-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-03-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-08-15","type":"ACTUAL"},"completionDateStruct":{"date":"2018-08-15","type":"ACTUAL"},"studyFirstSubmitDate":"2017-01-03","studyFirstSubmitQcDate":"2017-01-04","studyFirstPostDateStruct":{"date":"2017-01-05","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-03-29","resultsFirstSubmitQcDate":"2021-03-29","resultsFirstPostDateStruct":{"date":"2021-04-26","type":"ACTUAL"},"dispFirstSubmitDate":"2020-03-09","dispFirstSubmitQcDate":"2020-03-09","dispFirstPostDateStruct":{"date":"2020-03-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-03-29","lastUpdatePostDateStruct":{"date":"2021-04-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Nexstim Ltd","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":true,"isUnapprovedDevice":true,"isUsExport":false},"descriptionModule":{"briefSummary":"A prospective, multi-center, randomized, sham-controlled, blinded study combining active Nexstim NBS-guided 1Hz rTMS or sham-rTMS targeting the healthy hemisphere with standardized task oriented rehabilitation will be conducted in patients with post-stroke motor impairment of the upper limb. The therapy will be provided for 6 weeks and primary outcome assessed 6 months later."},"conditionsModule":{"conditions":["Ischemic Stroke"],"keywords":["Stroke","rTMS","Motor rehabilitation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":60,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Active","type":"ACTIVE_COMPARATOR","description":"Intervention: Device: NBS-guided rTMS + task-oriented rehabilitation","interventionNames":["Device: Nexstim NBS guided active rTMS"]},{"label":"Control","type":"SHAM_COMPARATOR","description":"Intervention: Device: NBS-guided Sham rTMS + task-oriented rehabilitation","interventionNames":["Device: Nexstim NBS guided sham rTMS"]}],"interventions":[{"type":"DEVICE","name":"Nexstim NBS guided active rTMS","description":"Nexstim NBS guided active rTMS + standardized task-oriented therapy","armGroupLabels":["Active"]},{"type":"DEVICE","name":"Nexstim NBS guided sham rTMS","description":"Nexstim NBS guided sham rTMS + standardized task-oriented therapy","armGroupLabels":["Control"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Upper Extremity Fugl-Meyer Score","description":"Range 0 to 65. HIgher scores indicate better function. Minimal clinically important difference = change of 5 points or more on scale. Outcome measure = proportion of patients in treatment arm gaining at least 5 points on scale between baseline and 6 months after end of treatment.","timeFrame":"Change from baseline to 6 months after end of treatment."}],"secondaryOutcomes":[{"measure":"Upper Extremity Fugl-Meyer Score","description":"Range 0-65. HIgher scores indicate better function.","timeFrame":"Change in score from baseline to 6 months after end of treatment"},{"measure":"Arm-Research Action Test (ARAT)","description":"Range 0 to 57. Higher scores indicate better function.","timeFrame":"Change in score from baseline to 6 months after end of treatment."},{"measure":"NIH Stroke Scale (NIHSS)","description":"National Institute of Health Stroke Scale - Motor Arm. Range 0 to 4. Lower score indicates better function.","timeFrame":"Change in score from baseline to 6 months after end of treatment"},{"measure":"Quality of Life Assessment: EQ-5D","description":"EuroQoL - EQ-5D score. Range 0 to 100. HIgher numbers indicate better quality of life.","timeFrame":"Change in score from baseline to 6 months after end of treatment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* ≥ 18 years of age\n* An ischemic stroke suffered 3-12 months prior to the study\n* No other known brain abnormalities by history;\n* A one-sided stroke resulting in upper extremity paresis\n* A Chedoke-McMaster Stroke Assessment arm stage and hand stage of 3-6 for the affected limb\n\nExclusion Criteria:\n\n* Implanted metallic parts of implanted electronic devices, including pacemakers, defibrillators, or implant medication pump;\n* Pregnant or trying to become pregnant; Lack of pregnancy established in females of child-bearing potential by a negative urine pregnancy test at screening.\n* Active alcohol abuse, illicit drug use or drug abuse or significant mental illness\n* Patients suffering from depression as measured by a score of \\>10 on the Patient Health Questionnaire (PHQ9). For clarity, patients diagnosed with depression which is controlled with stable anti-depressive medication and in whom PHQ9 is \\<10 are eligible to participate in the trial.\n* History of epilepsy, defined as at least two unprovoked seizures occurring greater than 24 hours apart or diagnosis of an epilepsy syndrome, OR a seizure within the last 12 months.\n* Any condition that would prevent the subject from giving voluntary informed consent;\n* An implanted brain stimulator;\n* Any metal in head with the exception of dental work or any ferromagnetic metal -elsewhere in the body;\n* Enrolled or plans to enroll in an interventional trial during this study;\n* Scalp wounds or infections;\n\n  * Claustrophobia precluding MRI;\n* A fixed contraction deformity in the affected limb that would prevent normal dexterity if patient were neurologically intact;\n* Excessive spasticity as indicated by the Modified Ashworth Spasticity (MAS) Scale \\>2/4 in either elbow flexors, wrist flexors or finger flexors of the affected limb;\n* Previous stroke with residual deficits (TIAs not a reason for exclusion);\n* Premorbid (retrospective) modified Rankin Scale (mRS) score ≥2 of any aetiology;\n* A concurrent progressive neurologic disorder, acute coronary syndrome, severe heart disease (NYHA Classification \\> 3), or other major medical condition,\n* Confirmed or suspected lower-limb fracture preventing mobilization, patients requiring palliative care\n* Patients planning to undergo any other occupational therapy during the 6 week active treatment period of the trial (see section 5.2 for study schedule) than what is provided in the study\n* A recent injection of botulinium toxin to the affected upper limb in the last 3 months, or the need of an injection of botulinum toxin anytime during the study period and follow up.\n* A recent injection of phenol to the affected upper limb in the last 6 months, or the need of an injection of phenol anytime during the study period and follow up.\n* Ataxia as measured by a score \\> 1 on item 7 (limb ataxia) of the NIH stroke scale.\n* Severe sensory deficits as measured by a score of 2 on item 8 of the NIH stroke scale.\n* Severe aphasia as measured by a score of \\> 2 on item 9 (best language) of the NIH stroke scale.\n* Severe neglect as measured by a score of 2 on item 11 (extinction and inattention) of the NIH stroke scale.\n* Patients unable to comprehend or follow verbal commands\n* Based on PI's or local physician's assessment patient unable to tolerate the trial procedure due to medical condition\n* A Mini mental status exam (MMSE) \\<25.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Rancho Los Amigos National Rehabilitation Center","city":"Downey","state":"California","zip":"90242","country":"United States","geoPoint":{"lat":33.94001,"lon":-118.13257}},{"facility":"Rehabilitation Institute of Chicago","city":"Chicago","state":"Illinois","zip":"60611","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Spaulding Rehabilitation Hospital","city":"Boston","state":"Massachusetts","zip":"02129","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Burke Medical Research Institute, Weill Cornell Neurology","city":"White Plains","state":"New York","zip":"10605","country":"United States","geoPoint":{"lat":41.03399,"lon":-73.76291}},{"facility":"University of Cincinnati","city":"Cincinnati","state":"Ohio","zip":"45267","country":"United States","geoPoint":{"lat":39.12713,"lon":-84.51435}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Active","description":"Intervention: Device: NBS-guided rTMS + task-oriented rehabilitation\n\nNexstim NBS guided active rTMS: Nexstim NBS guided active rTMS + standardized task-oriented therapy"},{"id":"FG001","title":"Control","description":"Intervention: Device: NBS-guided Sham rTMS + task-oriented rehabilitation\n\nNexstim NBS guided sham rTMS: Nexstim NBS guided sham rTMS + standardized task-oriented therapy"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"29"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"1 subject withdrew consent before baseline visit. 2 subjects completed treatment but were lost during follow-up","numSubjects":"28"},{"groupId":"FG001","comment":"1 subject withdrew consent prior to baseline visit","numSubjects":"28"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Active","description":"Intervention: Device: NBS-guided rTMS + task-oriented rehabilitation\n\nNexstim NBS guided active rTMS: Nexstim NBS guided active rTMS + standardized task-oriented therapy"},{"id":"BG001","title":"Control","description":"Intervention: Device: NBS-guided Sham rTMS + task-oriented rehabilitation\n\nNexstim NBS guided sham rTMS: Nexstim NBS guided sham rTMS + standardized task-oriented therapy"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"60"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"59.0","spread":"9.5"},{"groupId":"BG001","value":"58.0","spread":"10.9"},{"groupId":"BG002","value":"58.5","spread":"10.2"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"60"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"18"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"42"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"60"}]}],"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"15"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"44"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Time from stroke","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"60"}]}],"categories":[{"title":"3-6 months","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"27"}]},{"title":"6-12 months","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"33"}]}]}]},{"title":"Upper extremity Fugl-Meyer score","populationDescription":"2 subjects ( 1 active, 1 sham withdraw consent prior to analysis of study specific baseline characteristics)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"58"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"37.4","spread":"12.7"},{"groupId":"BG001","value":"42.2","spread":"13.2"},{"groupId":"BG002","value":"39.7","spread":"13.1"}]}]}]},{"title":"Action Research Arm Test","populationDescription":"2 subjects ( 1 active, 1 sham withdraw consent prior to analysis of study specific baseline characteristics)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"58"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"28.9","spread":"17.7"},{"groupId":"BG001","value":"34.7","spread":"16.7"},{"groupId":"BG002","value":"31.7","spread":"17.3"}]}]}]},{"title":"NIHSS","populationDescription":"2 subjects ( 1 active, 1 sham withdraw consent prior to analysis of study specific baseline characteristics)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"58"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"2.23","spread":"1.74"},{"groupId":"BG001","value":"1.86","spread":"1.88"},{"groupId":"BG002","value":"2.05","spread":"1.80"}]}]}]},{"title":"EQ-5D","populationDescription":"2 subjects ( 1 active, 1 sham withdraw consent prior to analysis of study specific baseline characteristics)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"58"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"61.8","spread":"19.9"},{"groupId":"BG001","value":"70.1","spread":"18.4"},{"groupId":"BG002","value":"65.8","spread":"19.5"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Upper Extremity Fugl-Meyer Score","description":"Range 0 to 65. HIgher scores indicate better function. Minimal clinically important difference = change of 5 points or more on scale. Outcome measure = proportion of patients in treatment arm gaining at least 5 points on scale between baseline and 6 months after end of treatment.","populationDescription":"Intent to treat population. All subjects completing the baseline visit.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Change from baseline to 6 months after end of treatment.","groups":[{"id":"OG000","title":"Active","description":"Intervention: Device: NBS-guided rTMS + task-oriented rehabilitation\n\nNexstim NBS guided active rTMS: Nexstim NBS guided active rTMS + standardized task-oriented therapy"},{"id":"OG001","title":"Control","description":"Intervention: Device: NBS-guided Sham rTMS + task-oriented rehabilitation\n\nNexstim NBS guided sham rTMS: Nexstim NBS guided sham rTMS + standardized task-oriented therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"28"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"14"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.62","statisticalMethod":"Chi-squared, Corrected"}]},{"type":"SECONDARY","title":"Upper Extremity Fugl-Meyer Score","description":"Range 0-65. HIgher scores indicate better function.","populationDescription":"Intent to treat population. All enrolled subjects who completed the baseline visit.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Change in score from baseline to 6 months after end of treatment","groups":[{"id":"OG000","title":"Active","description":"Intervention: Device: NBS-guided rTMS + task-oriented rehabilitation\n\nNexstim NBS guided active rTMS: Nexstim NBS guided active rTMS + standardized task-oriented therapy"},{"id":"OG001","title":"Control","description":"Intervention: Device: NBS-guided Sham rTMS + task-oriented rehabilitation\n\nNexstim NBS guided sham rTMS: Nexstim NBS guided sham rTMS + standardized task-oriented therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"28"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.17","spread":"8.24"},{"groupId":"OG001","value":"5.00","spread":"7.29"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.46","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"SECONDARY","title":"Arm-Research Action Test (ARAT)","description":"Range 0 to 57. Higher scores indicate better function.","populationDescription":"Intent to treat population. All subjects completing the baseline visit.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Change in score from baseline to 6 months after end of treatment.","groups":[{"id":"OG000","title":"Active","description":"Intervention: Device: NBS-guided rTMS + task-oriented rehabilitation\n\nNexstim NBS guided active rTMS: Nexstim NBS guided active rTMS + standardized task-oriented therapy"},{"id":"OG001","title":"Control","description":"Intervention: Device: NBS-guided Sham rTMS + task-oriented rehabilitation\n\nNexstim NBS guided sham rTMS: Nexstim NBS guided sham rTMS + standardized task-oriented therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"28"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.93","spread":"6.99"},{"groupId":"OG001","value":"5.68","spread":"7.96"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.54","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"SECONDARY","title":"NIH Stroke Scale (NIHSS)","description":"National Institute of Health Stroke Scale - Motor Arm. Range 0 to 4. Lower score indicates better function.","populationDescription":"Intent to treat. All subject completing the baseline visit.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Change in score from baseline to 6 months after end of treatment","groups":[{"id":"OG000","title":"Active","description":"Intervention: Device: NBS-guided rTMS + task-oriented rehabilitation\n\nNexstim NBS guided active rTMS: Nexstim NBS guided active rTMS + standardized task-oriented therapy"},{"id":"OG001","title":"Control","description":"Intervention: Device: NBS-guided Sham rTMS + task-oriented rehabilitation\n\nNexstim NBS guided sham rTMS: Nexstim NBS guided sham rTMS + standardized task-oriented therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"28"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.62","spread":"1.35"},{"groupId":"OG001","value":"-0.50","spread":"1.40"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.59","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"SECONDARY","title":"Quality of Life Assessment: EQ-5D","description":"EuroQoL - EQ-5D score. Range 0 to 100. HIgher numbers indicate better quality of life.","populationDescription":"Intent to treat - all subjects completing the baseline visit.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Change in score from baseline to 6 months after end of treatment","groups":[{"id":"OG000","title":"Active","description":"Intervention: Device: NBS-guided rTMS + task-oriented rehabilitation\n\nNexstim NBS guided active rTMS: Nexstim NBS guided active rTMS + standardized task-oriented therapy"},{"id":"OG001","title":"Control","description":"Intervention: Device: NBS-guided Sham rTMS + task-oriented rehabilitation\n\nNexstim NBS guided sham rTMS: Nexstim NBS guided sham rTMS + standardized task-oriented therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"28"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.86","spread":"21.09"},{"groupId":"OG001","value":"8.96","spread":"18.80"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.70","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From baseline until 6 months after end of treatment.","eventGroups":[{"id":"EG000","title":"Active","description":"Intervention: Device: NBS-guided rTMS + task-oriented rehabilitation\n\nNexstim NBS guided active rTMS: Nexstim NBS guided active rTMS + standardized task-oriented therapy","deathsNumAffected":0,"deathsNumAtRisk":30,"seriousNumAffected":4,"seriousNumAtRisk":30,"otherNumAffected":5,"otherNumAtRisk":30},{"id":"EG001","title":"Control","description":"Intervention: Device: NBS-guided Sham rTMS + task-oriented rehabilitation\n\nNexstim NBS guided sham rTMS: Nexstim NBS guided sham rTMS + standardized task-oriented therapy","deathsNumAffected":0,"deathsNumAtRisk":28,"seriousNumAffected":5,"seriousNumAtRisk":28,"otherNumAffected":2,"otherNumAtRisk":28}],"seriousEvents":[{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":28}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Pericardial Effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":28}]},{"term":"Diplopia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":28}]},{"term":"Bacterial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":28}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":28}]},{"term":"Self-injurious ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Acute Kidney Injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":28}]}],"otherEvents":[{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":30},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":30},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":28}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":28}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":28}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":30},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":28}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Vice President, Medical Affairs","organization":"Nexstim Plc","email":"jarmo.laine@nexstim.com","phone":"+358927271710"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2018-08-08","uploadDate":"2021-03-29T01:32","filename":"Prot_SAP_000.pdf","size":840392}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":true}